This is an HTML version of an attachment to the Official Information request 'Informed Consent #17 - New list of adverse events'.




 
 
133 Molesworth Street 
PO Box 5013 
Wellington 6140 
New Zealand 
T+64 4 496 2000 
 
17 January 2022 
 
 
Annie Weston 
 
 
By email:  [email address] 
 
 
[email address] 
 
 
[email address] 
 
 
[email address] 
 
 
[email address] 
 
 
[FYI request #17865 email] 
 
 
[email address] 
 
 
[email address] 
 
 
[email address] 
 
 
[email address] 
  
Ref:   
H202117251 
 
Tēnā koe Annie 
 
Response to your requests for official information 
 
Thank you for your requests under the Official Information Act 1982 (the Act) on 3 December 
2021, 6 December 2021, 7 December 2021 (10.38am, 11.15am and 12.58pm); 10 December 
2021 (11.03am and 11.19am), 12 December 2021, 16 December 2021, and 20 December 
2021. The two requests on 10 December 2021 were made to the Minister of Health, Hon 
Andrew Little, and the request on 12 December 2021 was made to the Department of the Prime 
Minister and Cabinet (DPMC), and subsequently transferred to the Ministry of Health (the 
Ministry) response.  
 
As these requests all relate to the Pfizer Comirnaty COVID-19 vaccine, the Ministry has 
consolidated your requests under section 16 of the Act. Your consolidated request is attached 
as Appendix 1.  
 
Given the size of your consolidated request, which runs to 10 pages, it might be refused under 
section 18 of the Act on the grounds that it would require the substantial collation of information. 
However, as required under section 18A of the Act, the Ministry is seeking under section 15 of 
the Act to provide you with the opportunity to rescope your request. In asking you to rescope 
your request, the Ministry asks you to consider the following points. 
 
The first point concerns the nature of requests under the Act. While the law allows New 
Zealanders to request official information from Ministers and government agencies, there is no 
requirement under the Act for the Ministry to create new information, compile information it does 
not hold, provide or prove an opinion or respond to hypothetical questions. Several of your 
questions are asking the Ministry to offer comment on statements made overseas or vaccine 
requirements in foreign jurisdictions. The Act does support requests where an opinion, comment 
or statement is put to the Ministry for response, couched as a request for information. Some of 
your questions fall into this category and are likely to be refused.  
 
Secondly, since the global pandemic began, the Ministry and other government agencies have 
proactively published a significant amount of information about COVID-19 that would answer 
many of your questions. I want to draw your attention to the following:   

 
•  Comprehensive information about New Zealand’s COVID-19 response, including 
vaccination, alert levels, overseas travel and departure tests, is available on the Unite 
against COVID-19 website at: www.covid19.govt.nz. 
 
•  The Department of the Prime Minister and Cabinet is the lead agency for the Al -of-
Government response to the COVID-19 pandemic and has published information about 
its work at: ht ps://dpmc.govt.nz/our-business-units/covid-19-group.  
 
•  COVID-19 case numbers are published daily by the Institute of Environmental Science 
and Research (ESR): https:/ nzcoviddashboard.esr.cri.nz/#!/ ESR has also published a 
wide range of other information about the SARs CoV-2 virus and its response work: 
www.esr.cri.nz/our-expertise/covid-19-response/. 
 
•  The Ministry also publishes COVID-19 case data (www.health.govt.nz/our-
work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-data-and-
statistics/covid-19-current-cases), COVID-19 Situation Reports 
(www.health.govt.nz/about-ministry/information-releases/general-information-
releases/covid-19-situation-reports-january-november-2020) and COVID-19 vaccination 
data (www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-
coronavirus/covid-19-data-and-statistics/covid-19-vaccine-data). 
 
•  New Zealand’s Medicines and Medical Devices Authority, Medsafe, has published a 
range of information on the approval of COVID-19 vaccines, including adverse events 
following immunisation (including deaths) at: www.medsafe.govt.nz/index.asp. 
Information about the voluntary reporting of adverse events is available at: 
www.medsafe.govt.nz/COVID-19/q-and-a-vaccine-safety.asp#data. It has also published 
the Consumer Medicine Information Summary (CMIS) that addresses your questions 
about the ingredients of the Comirnaty vaccine at: 
www.medsafe.govt.nz/Consumers/cmi/c/comirnaty.pdf 
 
•  Medsafe has also published information about thrombosis 
(www.medsafe.govt.nz/Consumers/educational-material/Thrombosis-with-
Thrombocytopenia-Syndrome.pdf), pregnancy 
(www.medsafe.govt.nz/safety/Alerts/covid-19-vaccination-in-pregnancy.asp), and 
myocarditis and pericarditis (www.medsafe.govt.nz/safety/Alerts/comirnaty-myocarditis-
alert.htm) among a range of topics.      
 
•  The Ministry has published responses to requests under the Act that cover many of the 
issues you have raised at: www.health.govt.nz/about-ministry/information-
releases/responses-of icial-information-act-requests. Specifically, several of your 
questions relate to a document published in the United States, namely the Cumulative 
Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) 
Received Through 28-Feb-2021. The Ministry has received several similar requests for 
information related to this document. A comprehensive response that addresses these 
parts of your request is publicly available at: 
www.health.govt.nz/system/files/documents/information-
release/h202117570_response_0.pdf 
  •  The Ministry has published a review of a range of scientific information on COVID-19-
related topics at: www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-
coronavirus/covid-19-resources-and-tools/covid-19-science-news.  
 
•  The Immunisation Handbook (chapter 5) contains a range of information and references 
to scientific literature about COVID-19 and COVID-19 vaccines. It is available at: 
www.health.govt.nz/our-work/immunisation-handbook-2020/5-coronavirus-disease-
covid-19 
Page 2 of 13 


 
•  The Ministry has published a range of information about pregnancy and breastfeeding, 
including:  
  www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-
coronavirus/covid-19-vaccines/covid-19-vaccine-health-advice/covid-19-vaccine-
pregnancy-and-breastfeeding  
  www.health.govt.nz/system/files/documents/pages/csu-13-sept-2021-vaccination-in-
pregnancy-is-not-associated-with-miscarriage.pdf 
  www.medsafe.govt.nz/safety/Alerts/covid-19-vaccination-in-pregnancy.asp 
   www.health.govt.nz/our-work/immunisation-handbook-2020/5-coronavirus-disease-
covid-19#23-4 (especially sections 5.2.2., 5.4.4. and 5.5.9. and the scientific 
references in these sections). 
 
•  Additionally, a range of peer reviewed scientific research about the COVID-19 virus and 
vaccines has been published on PubMed by the National Center for Biotechnology 
Information at the National Institutes of Health in the United States at: 
https:/ pubmed.ncbi.nlm.nih.gov. Specifically, a search on this website for this phrase: 
“Safety and Ef icacy of the BNT162b2 mRNA Covid-19 Vaccine" provides a wealth of 
scientific literature on the safety and efficacy of the Pfizer Comirnaty vaccine. 
 
I look forward to your response by 21 January 2022. 
 
Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any 
decisions made under this request. The Ombudsman may be contacted by email at: 
[email address] or by calling 0800 802 602. 
 
Nāku noa, nā 
 
Jan Torres 
Acting Manager, OIA Services 
Office of the Director-General 
 
 
Page 3 of 13 

Appendix 1 
 
Request – 3 December 2021 

 
It is a simple question on your policy - it does not require opinion, comment, argument, or a 
hypothetical statement. I simply want to know why the Govt does not require anyone to report 
adverse effects from taking the vaccines. 
 
Request – 6 December 2021 
 
https://www.medsafe.govt.nz/COVID-19/active-monitoring.asp 
 
The Post Vaccine Symptom Check was paused on 5 November 2021 in order to allow for a 
review of the survey design and the data received to date. This review wil  ensure the survey 
can continue to support the roll-out of the vaccine into the future. Thank you to everyone who 
has participated so far. The Post Vaccine Symptom Check wil  resume in early December 
2021.” 
 
My questions please: 
1) 
Wil  the Post Vaccine Symptom Check contain the data from November or was this not 
collected for some reason.  I am particularly interested in viewing the vaccine deaths and 
injuries that occurred after the “Super Saturday” event on 16 October 2021. 
2) 
The full side effects that are listed and linked on the webpage stil  don’t list death.  When 
wil  you update this please? 
3) 
The results from the survey are likely to be displayed in October 2021 according to the 
webpage which was revised on 17 November 2021.  When wil  they actual y be available 
to view please? 
 
Request – 7 December 2021 10.38am 
 
Pfizer have allegedly released a 38 page document that details 100 plus new adverse events 
from the vaccine that pose long term risks to health. The document was finalised on 30 April 
2021 before the Govt mandated vaccines.  The title of the document is as per below and at this 
stage has not been censored by search engines. 
 
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS 
OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021 
 
Questions please: 
1) 
Does the single source of truth determine that this is a legitimate document from Pfizer 
and is not misinformation? 
 
2) 
If it is legitimate when was the Govt supplied with this information? 
 
Request – 7 December 2021 11.15am 

 
According to Pfizer's recently released analysis the below is a list of the adverse events of 
special interest that could occur after taking their vaccine. 
 
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS 
OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021 
 
Question please: 
 
When wil  these adverse events be added to the New Zealand Data Sheet for Comirnaty? 
https://www.medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf 
 
Page 4 of 13 

APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST 
1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic 
neuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa;Acquired epileptic 
aphasia;Acute cutaneous lupus erythematosus;Acute disseminated encephalomyelitis;Acute 
encephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilic 
dermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute haemorrhagic 
oedema of infancy;Acute kidney injury;Acute macular outer retinopathy;Acute motor axonal 
neuropathy;Acute motor-sensory axonal neuropathy;Acute myocardial infarction;Acute 
respiratory distress syndrome;Acute respiratory failure;Addison's disease;Administration site 
thrombosis;Administration site vasculitis;Adrenal thrombosis;Adverse event following 
immunisation;Ageusia;Agranulocytosis;Air 
embolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholic 
seizure;Al ergic bronchopulmonary mycosis;Al ergic oedema;Al oimmune hepatitis;Alopecia 
areata;Alpers disease;Alveolar proteinosis;Ammonia abnormal;Ammonia increased;Amniotic 
cavity infection;Amygdalohippocampectomy;Amyloid 
arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylactic 
shock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoid 
shock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathic neuropathy;Ankylosing 
spondylitis;Anosmia;Antiacetylcholine receptor antibody positive;Anti-actin antibody 
positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia antibody positive;Anti-cyclic 
citrullinated peptide antibody positive;Anti-epithelial antibody positive;Anti-erythrocyte antibody 
positive;Anti-exosome complex antibody positive;Anti- GAD antibody negative;Anti-GAD 
antibody positive;Anti-ganglioside antibody positive;Antigliadin antibody positive;Anti-glomerular 
basement membrane antibody positive;Anti-glomerular basement membrane disease;Anti-
glycyl-tRNA synthetase antibody positive;Anti-HLA antibody test positive;Anti-IA2 antibody 
positive;Anti-insulin antibody increased;Anti-insulin antibody positive;Anti-insulin receptor 
antibody increased;Anti nsulin receptor antibody positive;Anti-interferon antibody negative;Anti-
interferon antibody positive;Anti-islet cell antibody positive;Antimitochondrial antibody 
positive;Anti-muscle specific kinase antibody positive;Anti-myelin-associated glycoprotein 
antibodies positive;Anti-myelin-associated glycoprotein associated 
polyneuropathy;Antimyocardial antibody positive;Anti-neuronal antibody positive;Antineutrophil 
cytoplasmic antibody increased;Antineutrophil cytoplasmic antibody positive;Anti-neutrophil 
cytoplasmic antibody positive vasculitis;Anti-NMDA antibody positive;Antinuclear antibody 
increased;Antinuclear antibody positive;Antiphospholipid antibodies positive;Antiphospholipid 
syndrome;Anti-platelet antibody positive;Anti-prothrombin antibody positive;Antiribosomal P 
antibody positive;Anti-RNA polymerase III antibody positive;Anti-saccharomyces cerevisiae 
antibody test positive;Anti-sperm antibody positive;Anti-SRP antibody positive;Antisynthetase 
syndrome;Anti-thyroid antibody positive;Anti-transglutaminase antibody increased;Anti-VGCC 
antibody positive;Anti- VGKC antibody positive;Anti-vimentin antibody positive;Antiviral 
prophylaxis;Antiviral treatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aortic 
thrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia;Application site 
thrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass 
thrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft site 
stenosis;Arteriovenous graft thrombosis;Arteritis;Arteritis Page 30 
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 ( 
GMT) 
FDA-CBER-2021-5683-0000083 
BNT162b2 
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page 
2 coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinus 
thrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferase 
increased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio index 
increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID- 
19;Ataxia;Atheroembolism;Atonic seizures;Atrial thrombosis;Atrophic thyroiditis;Atypical benign 
partial epilepsy;Atypical pneumonia;Aura;Autoantibody positive;Autoimmune 
anaemia;Autoimmune aplastic anaemia;Autoimmune arthritis;Autoimmune blistering 
disease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune demyelinating 
Page 5 of 13 

disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune 
encephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eye 
disorder;Autoimmune haemolytic anaemia;Autoimmune heparin-induced 
thrombocytopenia;Autoimmune hepatitis;Autoimmune hyperlipidaemia;Autoimmune 
hypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmune 
lymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune 
nephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmune 
pancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmune 
retinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmune 
uveitis;Autoinflammation with infantile enterocolitis;Autoinflammatory disease;Automatism 
epileptic;Autonomic nervous system imbalance;Autonomic seizure;Axial 
spondyloarthritis;Axil ary vein thrombosis;Axonal and demyelinating polyneuropathy;Axonal 
neuropathy;Bacterascites;Baltic myoclonic epilepsy;Band sensation;Basedow's disease;Basilar 
artery thrombosis;Basophilopenia;B-cell aplasia;Behcet's syndrome;Benign ethnic 
neutropenia;Benign familial neonatal convulsions;Benign familial pemphigus;Benign rolandic 
epilepsy;Beta-2 glycoprotein antibody positive;Bickerstaff's encephalitis;Bile output 
abnormal;Bile output decreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin 
conjugated increased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase 
deficiency;Birdshot chorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline 
phosphatase increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin 
unconjugated increased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood 
pressure decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue 
toe syndrome;Brachiocephalic vein thrombosis;Brain stem embolism;Brain stem 
thrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitis 
mycoplasmal;Bronchitis viral;Bronchopulmonary aspergil osis allergic;Bronchospasm;Budd- 
Chiari syndrome;Bulbar palsy;Butterfly rash;C1q nephropathy;Caesarean section;Calcium 
embolism;Capillaritis;Caplan's syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiac 
failure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenic 
shock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratory arrest;Cardio-
respiratory distress;Cardiovascular insufficiency;Carotid arterial embolus;Carotid artery 
thrombosis;Cataplexy;Catheter site thrombosis;Catheter site vasculitis;Cavernous sinus 
thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cement embolism;Central nervous 
system lupus;Central nervous system vasculitis;Cerebellar artery thrombosis;Cerebellar 
embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebral artery embolism;Cerebral 
artery thrombosis;Cerebral gas embolism;Cerebral microembolism;Cerebral septic 
infarct;Cerebral thrombosis;Cerebral venous sinus thrombosis;Cerebral venous 
thrombosis;Cerebrospinal thrombotic Page 31 090177e196ea1800\Approved\Approved On: 30-
Apr-2021 09:26 ( 
GMT) 
FDA-CBER-2021-5683-0000084 
BNT162b2 
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page 
3 tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;Child- 
Pugh-Turcotte score abnormal;Child-Pugh-Turcotte score 
increased;Chil blains;Choking;Choking sensation;Cholangitis sclerosing;Chronic autoimmune 
glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatigue syndrome;Chronic 
gastritis;Chronic inflammatory demyelinating polyradiculoneuropathy;Chronic lymphocytic 
inflammation with pontine perivascular enhancement responsive to steroids;Chronic recurrent 
multifocal osteomyelitis;Chronic respiratory failure;Chronic spontaneous urticaria;Circulatory 
collapse;Circumoral oedema;Circumoral swelling;Clinically isolated syndrome;Clonic 
convulsion;Coeliac disease;Cogan's syndrome;Cold agglutinins positive;Cold type haemolytic 
anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagen 
disorder;Collagen-vascular disease;Complement factor abnormal;Complement factor C1 
decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complement 
factor C4 decreased;Complement factor decreased;Computerised tomogram liver 
abnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylvian 
syndrome;Congenital herpes simplex infection;Congenital myasthenic syndrome;Congenital 
Page 6 of 13 

varicella infection;Congestive hepatopathy;Convulsion in childhood;Convulsions 
local;Convulsive threshold lowered;Coombs positive haemolytic anaemia;Coronary artery 
disease;Coronary artery embolism;Coronary artery thrombosis;Coronary bypass 
thrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirus test 
positive;Corpus callosotomy;Cough;Cough variant asthma;COVID-19;COVID-19 
immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial nerve 
disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CREST syndrome;Crohn's 
disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal band present;CSWS 
syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneous 
sarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokine 
release syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acute 
inflammatory syndrome;Death neonatal;Deep vein thrombosis;Deep vein thrombosis 
postoperative;Deficiency of bile secretion;Deja vu;Demyelinating 
polyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitis 
herpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetes 
mellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis amyloidosis;Dialysis membrane 
reaction;Diastolic hypotension;Diffuse vasculitis;Digital pitting scar;Disseminated intravascular 
coagulation;Disseminated intravascular coagulation in newborn;Disseminated neonatal herpes 
simplex;Disseminated varicella;Disseminated varicella zoster vaccine virus 
infection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortex 
syndrome;Double stranded DNA antibody positive;Dreamy state;Dressler's syndrome;Drop 
attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy with 
burst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Embolic 
cerebellar infarction;Embolic cerebral infarction;Embolic pneumonia;Embolic 
stroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitis 
allergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitis 
haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post 
immunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrine 
ophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacter 
pneumonia;Enterocolitis;Enteropathic spondylitis;Eosinopenia;Eosinophilic 
Page 32 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 ( 
GMT) 
FDA-CBER-2021-5683-0000085 
BNT162b2 
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page 
4 fasci tis;Eosinophilic granulomatosis with polyangiitis;Eosinophilic 
oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonic 
seizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythema 
multiforme;Erythema nodosum;Evans syndrome;Exanthema subitum;Expanded disability status 
scale score decreased;Expanded disability status scale score increased;Exposure to 
communicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eye swelling;Eyelid 
oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonic seizure;Fat 
embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrile 
neutropenia;Felty's syndrome;Femoral artery embolism;Fibril ary 
glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focal 
dyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetor 
hepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes 
mellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity test 
decreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferase 
increased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onset non-
motor seizure;Generalised tonic-clonic seizure;Genital herpes;Genital herpes simplex;Genital 
herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritis 
membranoproliferative;Glomerulonephritis membranous;Glomerulonephritis rapidly 
progressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiency 
syndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2 
gangliosidosis;Goodpasture's syndrome;Graft thrombosis;Granulocytopenia;Granulocytopenia 
neonatal;Granulomatosis with polyangiitis;Granulomatous dermatitis;Grey matter 
Page 7 of 13 

heterotopia;Guanase increased;Guil ain- Barre syndrome;Haemolytic 
anaemia;Haemophagocytic lymphohistiocytosis;Haemorrhage;Haemorrhagic 
ascites;Haemorrhagic disorder;Haemorrhagic pneumonia;Haemorrhagic varicella 
syndrome;Haemorrhagic vasculitis;Hantavirus pulmonary infection;Hashimoto's 
encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;Henoch- 
Schonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-induced 
thrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flow 
decreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzyme 
decreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosis marker 
increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatic hypertrophy;Hepatic 
hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepatic pain;Hepatic 
sequestration;Hepatic vascular resistance increased;Hepatic vascular thrombosis;Hepatic vein 
embolism;Hepatic vein thrombosis;Hepatic venous pressure gradient abnormal;Hepatic venous 
pressure gradient increased;Hepatitis;Hepatobiliary scan 
abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esterase 
inhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpes 
ophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex cervicitis;Herpes 
simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpes simplex 
hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpes simplex 
meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplex oesophagitis;Herpes 
simplex otitis externa;Herpes simplex pharyngitis;Herpes simplex pneumonia;Herpes simplex 
reactivation;Herpes simplex sepsis;Herpes simplex viraemia;Herpes simplex virus conjunctivitis 
neonatal;Herpes simplex visceral;Herpes virus Page 33 
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 ( 
GMT) 
FDA-CBER-2021-5683-0000086 
BNT162b2 
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page 
5 infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection 
neurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zoster 
meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising retinopathy;Herpes 
zoster oticus;Herpes zoster pharyngitis;Herpes zoster reactivation;Herpetic 
radiculopathy;Histone antibody positive;Hoigne's syndrome;Human herpesvirus 6 
encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection reactivation;Human 
herpesvirus 7 infection;Human herpesvirus 8 
infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia 
benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity 
vasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;H 
ypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal 
nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive 
crisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4 
lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic 
neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;II rd nerve 
paralysis;I Ird nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immunemediated 
adverse reaction;Immune-mediated cholangitis;Immune-mediated cholestasis;Immune-
mediated cytopenia;Immune-mediated encephalitis;Immune-mediated encephalopathy;Immune-
mediated endocrinopathy;Immune-mediated enterocolitis;Immunemediated gastritis;Immune-
mediated hepatic disorder;Immune-mediated hepatitis;Immunemediated 
hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated myocarditis;Immune-
mediated myositis;Immune-mediated nephritis;Immune-mediated neuropathy;Immune-mediated 
pancreatitis;Immune-mediated pneumonitis;Immune-mediated renal disorder;Immune-mediated 
thyroiditis;Immune-mediated uveitis;Immunoglobulin G4 related disease;Immunoglobulins 
abnormal;Implant site thrombosis;Inclusion body myositis;Infantile genetic 
agranulocytosis;Infantile spasms;Infected vasculitis;Infective 
thrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion site 
vasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instil ation site 
thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous dermatitis;Interstitial lung 
Page 8 of 13 

disease;Intracardiac mass;Intracardiac thrombus;Intracranial pressure increased;Intrapericardial 
thrombosis;Intrinsic factor antibody abnormal;Intrinsic factor antibody positive;IPEX 
syndrome;Irregular breathing;IRVAN syndrome;IVth nerve paralysis;IVth nerve paresis;JC 
polyomavirus test positive;JC virus CSF test positive;Jeavons syndrome;Jugular vein 
embolism;Jugular vein thrombosis;Juvenile idiopathic arthritis;Juvenile myoclonic 
epilepsy;Juvenile polymyositis;Juvenile psoriatic arthritis;Juvenile spondyloarthritis;Kaposi 
sarcoma inflammatory cytokine syndrome;Kawasaki's disease;Kayser-Fleischer 
ring;Keratoderma blenorrhagica;Ketosisprone diabetes mellitus;Kounis syndrome;Lafora's 
myoclonic epilepsy;Lambl's excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal 
rheumatoid arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in 
adults;LE cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase 
increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia 
neonatal;Lewis-Sumner syndrome;Lhermit e's sign;Lichen planopilaris;Lichen planus;Lichen 
sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function test 
abnormal;Liver function test decreased;Liver function test increased;Liver induration;Liver 
injury;Liver iron concentration abnormal;Liver iron concentration Page 34 
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 ( 
GMT) 
FDA-CBER-2021-5683-0000087 
BNT162b2 
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page 
6 increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver scan abnormal;Liver 
tenderness;Low birth weight baby;Lower respiratory tract herpes infection;Lower respiratory 
tract infection;Lower respiratory tract infection viral;Lung abscess;Lupoid hepatic cirrhosis;Lupus 
cystitis;Lupus encephalitis;Lupus endocarditis;Lupus enteritis;Lupus hepatitis;Lupus 
myocarditis;Lupus myositis;Lupus nephritis;Lupus pancreatitis;Lupus pleurisy;Lupus 
pneumonitis;Lupus vasculitis;Lupus-like syndrome;Lymphocytic hypophysitis;Lymphocytopenia 
neonatal;Lymphopenia;MAGIC syndrome;Magnetic resonance imaging liver abnormal;Magnetic 
resonance proton density fat fraction measurement;Mahler sign;Manufacturing laboratory 
analytical testing issue;Manufacturing materials issue;Manufacturing production issue;Marburg's 
variant multiple sclerosis;Marchiafava-Bignami disease;Marine Lenhart syndrome;Mastocytic 
enterocolitis;Maternal exposure during pregnancy;Medical device site thrombosis;Medical 
device site vasculitis;MELAS syndrome;Meningitis;Meningitis aseptic;Meningitis 
herpes;Meningoencephalitis herpes simplex neonatal;Meningoencephalitis 
herpetic;Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test 
positive;Mesangioproliferative glomerulonephritis;Mesenteric artery embolism;Mesenteric artery 
thrombosis;Mesenteric vein thrombosis;Metapneumovirus infection;Metastatic cutaneous 
Crohn's disease;Metastatic pulmonary embolism;Microangiopathy;Microembolism;Microscopic 
polyangiitis;Middle East respiratory syndrome;Migraine-triggered seizure;Miliary 
pneumonia;Mil er Fisher syndrome;Mitochondrial aspartate aminotransferase increased;Mixed 
connective tissue disease;Model for end stage liver disease score abnormal;Model for end 
stage liver disease score increased;Molar ratio of total branched-chain amino acid to 
tyrosine;Molybdenum cofactor deficiency;Monocytopenia;Mononeuritis;Mononeuropathy 
multiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocal motor 
neuropathy;Multiple organ dysfunction syndrome;Multiple sclerosis;Multiple sclerosis 
relapse;Multiple sclerosis relapse prophylaxis;Multiple subpial transection;Multisystem 
inflammatory syndrome in children;Muscular sarcoidosis;Myasthenia gravis;Myasthenia gravis 
crisis;Myasthenia gravis neonatal;Myasthenic syndrome;Myelitis;Myelitis transverse;Myocardial 
infarction;Myocarditis;Myocarditis post infection;Myoclonic epilepsy;Myoclonic epilepsy and 
ragged-red fibres;Myokymia;Myositis;Narcolepsy;Nasal 
herpes;Nasal obstruction;Necrotising herpetic retinopathy;Neonatal Crohn's disease;Neonatal 
epileptic seizure;Neonatal lupus erythematosus;Neonatal mucocutaneous herpes 
simplex;Neonatal pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemic 
fibrosis;Neuralgic amyotrophy;Neuritis;Neuritis cranial;Neuromyelitis optica pseudo 
relapse;Neuromyelitis optica spectrum disorder;Neuromyotonia;Neuronal 
neuropathy;Neuropathy peripheral;Neuropathy, ataxia, retinitis pigmentosa 
syndrome;Neuropsychiatric lupus;Neurosarcoidosis;Neutropenia;Neutropenia 
Page 9 of 13 

neonatal;Neutropenic colitis;Neutropenic infection;Neutropenic sepsis;Nodular rash;Nodular 
vasculitis;Noninfectious myelitis;Noninfective encephalitis;Noninfective 
encephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary embolism;Occupational 
exposure to communicable disease;Occupational exposure to SARS-CoV-2;Ocular 
hyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular sarcoidosis;Ocular 
vasculitis;Oculofacial paralysis;Oedema;Oedema blister;Oedema due to hepatic 
disease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery thrombosis;Ophthalmic 
herpes simplex;Ophthalmic herpes zoster;Ophthalmic vein thrombosis;Optic neuritis;Optic Page 
35 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 ( 
GMT) 
FDA-CBER-2021-5683-0000088 
BNT162b2 
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page 
7 neuropathy;Optic perineuritis;Oral herpes;Oral lichen planus;Oropharyngeal 
oedema;Oropharyngeal spasm;Oropharyngeal swelling;Osmotic demyelination 
syndrome;Ovarian vein thrombosis;Overlap syndrome;Paediatric autoimmune neuropsychiatric 
disorders associated with streptococcal infection;Paget-Schroetter syndrome;Palindromic 
rheumatism;Palisaded neutrophilic granulomatous dermatitis;Palmoplantar 
keratoderma;Palpable purpura;Pancreatitis;Panencephalitis;Papil ophlebitis;Paracancerous 
pneumonia;Paradoxical embolism;Parainfluenzae viral laryngotracheobronchitis;Paraneoplastic 
dermatomyositis;Paraneoplastic pemphigus;Paraneoplastic thrombosis;Paresis cranial 
nerve;Parietal cell antibody positive;Paroxysmal nocturnal haemoglobinuria;Partial 
seizures;Partial seizures with secondary generalisation;Patient isolation;Pelvic venous 
thrombosis;Pemphigoid;Pemphigus;Penile vein thrombosis;Pericarditis;Pericarditis 
lupus;Perihepatic discomfort;Periorbital oedema;Periorbital swelling;Peripheral artery 
thrombosis;Peripheral embolism;Peripheral ischaemia;Peripheral vein thrombus 
extension;Periportal oedema;Peritoneal fluid protein abnormal;Peritoneal fluid protein 
decreased;Peritoneal fluid protein increased;Peritonitis lupus;Pernicious anaemia;Petit mal 
epilepsy;Pharyngeal oedema;Pharyngeal swelling;Pityriasis lichenoides et varioliformis 
acuta;Placenta praevia;Pleuroparenchymal fibroelastosis;Pneumobilia;Pneumonia;Pneumonia 
adenoviral;Pneumonia cytomegaloviral;Pneumonia herpes viral;Pneumonia 
influenzal;Pneumonia measles;Pneumonia mycoplasmal;Pneumonia necrotising;Pneumonia 
parainfluenzae viral;Pneumonia respiratory syncytial viral;Pneumonia viral;POEMS 
syndrome;Polyarteritis nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmune syndrome 
type I;Polyglandular autoimmune syndrome type II;Polyglandular autoimmune syndrome type 
II ;Polyglandular disorder;Polymicrogyria;Polymyalgia 
rheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic progressive;Portal 
pyaemia;Portal vein embolism;Portal vein flow decreased;Portal vein pressure increased;Portal 
vein thrombosis;Portosplenomesenteric venous thrombosis;Post procedural hypotension;Post 
procedural pneumonia;Post procedural pulmonary embolism;Post stroke epilepsy;Post stroke 
seizure;Post thrombotic retinopathy;Post thrombotic syndrome;Post viral fatigue 
syndrome;Postictal headache;Postictal paralysis;Postictal psychosis;Postictal 
state;Postoperative respiratory distress;Postoperative respiratory failure;Postoperative 
thrombosis;Postpartum thrombosis;Postpartum venous thrombosis;Postpericardiotomy 
syndrome;Post-traumatic epilepsy;Postural orthostatic tachycardia syndrome;Precerebral artery 
thrombosis;Pre-eclampsia;Preictal state;Premature labour;Premature menopause;Primary 
amyloidosis;Primary biliary cholangitis;Primary progressive multiple sclerosis;Procedural 
shock;Proctitis herpes;Proctitis ulcerative;Product availability issue;Product distribution 
issue;Product supply issue;Progressive facial hemiatrophy;Progressive multifocal 
leukoencephalopathy;Progressive multiple sclerosis;Progressive relapsing multiple 
sclerosis;Prosthetic cardiac valve thrombosis;Pruritus;Pruritus 
allergic;Pseudovasculitis;Psoriasis;Psoriatic 
arthropathy;Pulmonary amyloidosis;Pulmonary artery thrombosis;Pulmonary 
embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary microemboli;Pulmonary oil 
microembolism;Pulmonary renal syndrome;Pulmonary sarcoidosis;Pulmonary sepsis;Pulmonary 
thrombosis;Pulmonary tumour thrombotic microangiopathy;Pulmonary vasculitis;Pulmonary 
veno-occlusive disease;Pulmonary venous thrombosis;Pyoderma gangrenosum;Pyostomatitis 
Page 10 of 13 

vegetans;Pyrexia;Quarantine;Radiation leukopenia;Radiculitis Page 36 
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 ( 
GMT) 
FDA-CBER-2021-5683-0000089 
BNT162b2 
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page 
8 brachial;Radiologically isolated syndrome;Rash;Rash erythematous;Rash pruritic;Rasmussen 
encephalitis;Raynaud's phenomenon;Reactive capil ary endothelial proliferation;Relapsing 
multiple sclerosis;Relapsing-remit ing multiple sclerosis;Renal amyloidosis;Renal arteritis;Renal 
artery thrombosis;Renal embolism;Renal failure;Renal vascular thrombosis;Renal 
vasculitis;Renal vein embolism;Renal vein thrombosis;Respiratory arrest;Respiratory 
disorder;Respiratory distress;Respiratory failure;Respiratory paralysis;Respiratory syncytial 
virus bronchiolitis;Respiratory syncytial virus bronchitis;Retinal artery embolism;Retinal artery 
occlusion;Retinal artery thrombosis;Retinal vascular thrombosis;Retinal vasculitis;Retinal vein 
occlusion;Retinal vein thrombosis;Retinol binding protein decreased;Retinopathy;Retrograde 
portal vein flow;Retroperitoneal fibrosis;Reversible airways obstruction;Reynold's 
syndrome;Rheumatic brain disease;Rheumatic disorder;Rheumatoid arthritis;Rheumatoid factor 
increased;Rheumatoid factor positive;Rheumatoid factor quantitative increased;Rheumatoid 
lung;Rheumatoid neutrophilic dermatosis;Rheumatoid nodule;Rheumatoid nodule 
removal;Rheumatoid scleritis;Rheumatoid vasculitis;Saccadic eye movement;SAPHO 
syndrome;Sarcoidosis;SARS-CoV-1 test;SARS-CoV-1 test negative;SARS-CoV-1 test 
positive;SARS-CoV-2 antibody test;SARS-CoV-2 antibody test negative;SARS-CoV-2 antibody 
test positive;SARS-CoV-2 carrier;SARS-CoV-2 sepsis;SARS-CoV-2 test;SARSCoV- 
2 test false negative;SARS-CoV-2 test false positive;SARS-CoV-2 test negative;SARSCoV- 
2 test positive;SARS-CoV-2 viraemia;Satoyoshi 
syndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma associated digital 
ulcer;Scleroderma renal crisis;Scleroderma-like reaction;Secondary amyloidosis;Secondary 
cerebellar degeneration;Secondary progressive multiple sclerosis;Segmented hyalinising 
vasculitis;Seizure;Seizure anoxic;Seizure cluster;Seizure like phenomena;Seizure 
prophylaxis;Sensation of foreign body;Septic embolus;Septic pulmonary embolism;Severe 
acute respiratory syndrome;Severe myoclonic epilepsy of infancy;Shock;Shock 
symptom;Shrinking lung syndrome;Shunt thrombosis;Silent thyroiditis;Simple partial 
seizures;Sjogren's syndrome;Skin swelling;SLE arthritis;Smooth muscle antibody 
positive;Sneezing;Spinal artery embolism;Spinal artery thrombosis;Splenic artery 
thrombosis;Splenic embolism;Splenic thrombosis;Splenic vein 
thrombosis;Spondylitis;Spondyloarthropathy;Spontaneous heparin-induced thrombocytopenia 
syndrome;Status epilepticus;Stevens-Johnson syndrome;Stif  leg syndrome;Stif  person 
syndrome;Stillbirth;Still's disease;Stoma site thrombosis;Stoma site vasculitis;Stress 
cardiomyopathy;Stridor;Subacute cutaneous lupus erythematosus;Subacute 
endocarditis;Subacute inflammatory demyelinating polyneuropathy;Subclavian artery 
embolism;Subclavian artery thrombosis;Subclavian vein thrombosis;Sudden unexplained death 
in epilepsy;Superior sagittal sinus thrombosis;Susac's syndrome;Suspected COVID- 
19;Swelling;Swelling face;Swelling of eyelid;Swollen tongue;Sympathetic ophthalmia;Systemic 
lupus erythematosus;Systemic lupus erythematosus disease activity index abnormal;Systemic 
lupus erythematosus disease activity index decreased;Systemic lupus erythematosus disease 
activity index increased;Systemic lupus erythematosus rash;Systemic scleroderma;Systemic 
sclerosis pulmonary;Tachycardia;Tachypnoea;Takayasu's arteritis;Temporal lobe 
epilepsy;Terminal ileitis;Testicular autoimmunity;Throat tightness;Thromboangiitis 
obliterans;Thrombocytopenia;Thrombocytopenic 
purpura;Thrombophlebitis;Thrombophlebitis migrans;Thrombophlebitis Page 37 
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 ( 
GMT) 
FDA-CBER-2021-5683-0000090 
BNT162b2 
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page 
9 neonatal;Thrombophlebitis septic;Thrombophlebitis superficial;Thromboplastin antibody 
positive;Thrombosis;Thrombosis corpora cavernosa;Thrombosis in device;Thrombosis 
Page 11 of 13 

mesenteric vessel;Thrombotic cerebral infarction;Thrombotic microangiopathy;Thrombotic 
stroke;Thrombotic thrombocytopenic purpura;Thyroid disorder;Thyroid stimulating 
immunoglobulin increased;Thyroiditis;Tongue amyloidosis;Tongue biting;Tongue oedema;Tonic 
clonic movements;Tonic convulsion;Tonic posturing;Topectomy;Total bile acids increased;Toxic 
epidermal necrolysis;Toxic leukoencephalopathy;Toxic oil syndrome;Tracheal 
obstruction;Tracheal oedema;Tracheobronchitis;Tracheobronchitis 
mycoplasmal;Tracheobronchitis viral;Transaminases abnormal;Transaminases 
increased;Transfusion-related alloimmune neutropenia;Transient epileptic amnesia;Transverse 
sinus thrombosis;Trigeminal nerve paresis;Trigeminal neuralgia;Trigeminal palsy;Truncus 
coeliacus thrombosis;Tuberous sclerosis complex;Tubulointerstitial nephritis and uveitis 
syndrome;Tumefactive multiple sclerosis;Tumour embolism;Tumour thrombosis;Type 1 
diabetes mellitus;Type I hypersensitivity;Type I I immune complex mediated reaction;Uhthoff's 
phenomenon;Ulcerative keratitis;Ultrasound liver abnormal;Umbilical cord thrombosis;Uncinate 
fits;Undif erentiated connective tissue disease;Upper airway obstruction;Urine bilirubin 
increased;Urobilinogen urine decreased;Urobilinogen urine increased;Urticaria;Urticaria 
papular;Urticarial vasculitis;Uterine rupture;Uveitis;Vaccination site thrombosis;Vaccination site 
vasculitis;Vagus nerve paralysis;Varicella;Varicella keratitis;Varicella post vaccine;Varicella 
zoster gastritis;Varicella zoster oesophagitis;Varicella zoster pneumonia;Varicella zoster 
sepsis;Varicella zoster virus infection;Vasa praevia;Vascular graft thrombosis;Vascular 
pseudoaneurysm thrombosis;Vascular purpura;Vascular stent thrombosis;Vasculitic 
rash;Vasculitic ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vena cava 
embolism;Vena cava thrombosis;Venous intravasation;Venous recanalisation;Venous 
thrombosis;Venous thrombosis in pregnancy;Venous thrombosis limb;Venous thrombosis 
neonatal;Vertebral artery thrombosis;Vessel puncture site thrombosis;Visceral venous 
thrombosis;VIth nerve paralysis;VIth nerve paresis;Vitiligo;Vocal cord paralysis;Vocal cord 
paresis;Vogt-Koyanagi-Harada disease;Warm type haemolytic anaemia;Wheezing;White nipple 
sign;XIth nerve paralysis;X-ray hepatobiliary abnormal;Young's syndrome;Zika virus associated 
Guil ain Barre syndrome. 
Page 38 090177e196ea1800\ 
 
Request – 7 December 2021 12.58pm 
 
The below webpage shows a list of 271 generic drugs known to interact with Pfizer’s vaccine. 
 
270 of them are moderate interactions meaning: 
 
“Moderately clinically significant. Usually avoid combinations; use it only under special 
circumstances.” 
 
Question:  Does the Govt regard this as misinformation please? 
 
https:/ scanmail.trustwave.com/?c=15517&d=4KOu4QHKqKP8GqmPUfENVCX2029rI5rnigQUL
zVAzQ&u=https%3a%2f%2fwww%2edrugs%2ecom%2fdrug-interactions%2fsars-cov-2-mrna-
tozinameran-vaccine%2cpfizer-biontech-covid-19-vaccine-index%2ehtml 
 
Request – 10 December 2021 11.03am (transferred from the Minister of Health) 
 
Regarding the Risk Management Plan for Comirnaty: 
 
https://www.medsafe.govt.nz/COVID-19/Comirnaty-RMP.pdf 
 
The plan refers to Table 1: List of important risks and missing information. 
 
Missing Information: 
 
-Use in pregnancy and while breast feeding -Use in immunocompromised patients -Use in frail 
patients with co-morbidities (eg, chronic obstructive pulmonary disease [COPD], diabetes, 
Page 12 of 13 

chronic neurological disease, cardiovascular disorders) -Use in patients with autoimmune or 
inflammatory disorders -Interaction with other vaccines -Long-term safety data 
 
Please can you advise when the “missing information” wil  be available to the public.   
 
You have a year of real world data to inform you. 
 
Request – 10 December 2021 11.19am (transferred from the Minister of Health) 

 
In Medsafe’s data sheet for Pfizer’s vaccine it mentions the below under: 
 
4.6 Fertility, pregnancy and lactation 
 
Fertility 
“In a combined fertility and developmental toxicity study, female rats were intramuscularly 
administered COMIRNATY prior to mating and during gestation (4 full human doses of 30 μg 
each, spanning between pre-mating day 21 and gestation day 20). SARS-CoV-2 neutralising 
antibodies were present in maternal animals from prior to mating to the end of the study on 
postnatal day 21 as well as in fetuses and of spring. There were no vaccine related effects on 
female fertility and pregnancy rate.” 
 
Pregnancy 
 
“Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, 
embryo/fetal development, parturition or post-natal development.” 
 
https://www.medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf 
 
Question please: 
 
What were the miscarriage and stil birth rates among the rats that were studied? 
 
Request – 23 December 2021 (transferred from the DPMC) 
 
“When did the Prime Minister receive the post-marketing information from Pfizer?” 
 
Request – 16 December 2021  

 
I understand serialization, in the context of a vaccine rollout, involves the identification of 
vaccine batches for the purposes of tracking and research.  
 
Is the NZ Govt serializing the Pfizer vaccine batches for efficacy and safety purposes please? 
 
Request – 20 December 2021  
 
On the Japanese “Instructions for the Covid-19 vaccination” it states: 
 
“This product contains an additive that has never been used in a vaccine before.” 
 
https:/ scanmail.trustwave.com/?c=15517&d=m4e_4YQtPbuqbvNRzgcgEBSwnQ2jLgcFBRpC4
T3XUA&u=https%3a%2f%2fwww%2emhlw%2ego%2ejp%2fcontent%2f000759294%2epdf 
 
My questions please: 
 
1) 
Does the Comirnaty vaccine used in NZ contain this additive? 
 
3) 
If so what is it? 
Page 13 of 13